Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer.
Thompson A, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Hardie G, Pusztai L, Moulder S, Dewar J, Hadad S. Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer. Journal Of Clinical Oncology 2011, 29: 534-534. DOI: 10.1200/jco.2011.29.15_suppl.534.Peer-Reviewed Original ResearchPrimary operable breast cancerOperable breast cancerNeoadjuvant metforminBreast cancerFinal analysisPathway analysisGene expressionMetforminKi67Cancer